SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure, with community sentiment shifting between aggressive short-selling and debate over whether current price levels represent a structural breakdown or a buying opportunity. Discussions are dominated by concerns over crowded positioning, potential contract renewals, and skepticism regarding valuation, as participants closely monitor key support levels to determine if the stock is nearing a bottom.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion Inc. is trending following the White House's announcement of new executive orders focused on quantum sensing and networking, which positions the company as a key beneficiary in the quantum sector. Investors are actively discussing the stock's long-term potential, its upcoming Russell 3000 inclusion, and the impact of government-backed quantum initiatives on the broader technology landscape.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as shareholders express deep frustration over the company's recent stock performance and leadership, while others point to institutional accumulation and speculative interest in upcoming oncology catalysts. Discussion remains heavily divided between those highlighting the company's attractive dividend yield and pipeline potential and those criticizing the perceived lack of share price appreciation under current management.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is seeing intense bullish momentum and institutional interest as traders front-run anticipated earnings, with active debate centered on whether memory demand is in a structural super-cycle or an overextended AI bubble. Community discussion is heavily divided between retail traders betting on continued supply-chain dominance and skepticism regarding long-term capex sustainability in the broader hyperscaler sector.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is experiencing significant market interest and volatility driven by its strategic role in national quantum computing initiatives, lucrative federal contracts, and new enterprise-focused AI partnerships. While the broader community is actively debating the stock's long-term valuation versus its legacy consulting business, bulls are emphasizing significant recent price target upgrades from major analysts as a signal for sustained growth.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is attracting significant attention as investors speculate on a potential take-private buyout while monitoring the impact of a high dividend yield and recent leadership changes. The community is actively debating the stock's turnaround potential, with many traders focusing on high short interest as a catalyst for a possible squeeze despite broader concerns over sector-wide challenges and competitive pressures.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing significant volatility and downward pressure as retail investors navigate a cooling post-IPO sentiment and concerns over valuation, with the community actively debating whether to hold long-term or exit as the stock tests lower support levels. Market participants are split between those viewing the decline as a standard mechanical unwinding of crowded positions and others who see it as a broader correction fueled by institutional positioning.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is experiencing heightened investor interest driven by positive Phase 3 data for its MDD therapeutic and anticipation of a series of upcoming pivotal trial milestones. The community is actively debating the company's long-term commercialization prospects and the impact of a recent major public offering, with many investors weighing the potential for a breakthrough against the risks of dilution and the competitive landscape for psychedelic-based medicine.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as the sector experiences heightened investor interest driven by recent government executive orders aimed at accelerating commercial quantum technology development. Community discussion is heavily focused on the long-term potential of the quantum computing infrastructure, with active debates centered on technical milestones, potential sector-wide dilution risks, and the strategic positioning of various hardware players.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending due to the convergence of an upcoming earnings report and the high-profile IPO of its partner Cerebras, sparking investor interest in its specialized data center and AI compute infrastructure model. The community is actively discussing the stock's low float and the potential for a valuation re-rate as it aligns with broader AI capacity demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026

Taysha Gene Therapies (TSHA) Reports Financial Results for Q1 2026...

Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) released its earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02...

Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High  - Here's What Happened

Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year High - What's Next...

Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-taysha-gene-therapies-inc-stock...

Taysha Gene Therapies (NASDAQ:TSHA) Hits New 12-Month High  - Should You Buy?

Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 1-Year High - Here's What Happened...

Taysha Gene Therapies Sees Unusually High Options Volume (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) was the target of some unusual options trading on Thursday. Stock investors acquired 6,277 call options on the company. This is an increase...

Taysha Gene Therapies (NASDAQ:TSHA) Sets New 12-Month High  - Still a Buy?

Taysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High - What's Next...

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 9% - Should You Buy?

Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Up 9% - Still a Buy...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Buy" by Brokerages

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) has received an average rating of "Buy" from the thirteen brokerages that are presently covering the firm, MarketBeat reports. One equities...

Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $892,000.00 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Get Free Report) insider Sukumar Nagendran sold 200,000 shares of the business's stock in a transaction dated Friday, April 10th. The shares were sold at an...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.53
Prev Close	$6.42
Open	$6.50
Dividend Yield	0.00%
50-Day Moving Average	$5.96
Beta	1.71
Avg. Volume	2.36M
PE Ratio	-16.20

52-Week High	$7.30
52-Week Low	$2.25
Market Capitalization	$1.84B
EPS (Annual)	-$0.3409
Price to Book	8.70
Revenue Per Employee	$98,717.17

Feed

News

Sentiment

Earnings

Fundamentals

Info

TSHATaysha Gene Therapies Inc

Latest TSHA News